|
|
British Journal of Cancer (2007) 97, 919-926.
doi:10.1038/sj.bjc.6603970 www.bjcancer.com Published online 11 September 2007
In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation
R Fanciullino1, S Giacometti1, C Mercier1, C Aubert1, C Blanquicett2, P Piccerelle3 and J Ciccolini1
1EA3286-Laboratoire de Pharmacocinétique, Université de la Méditerranée, Marseille, France
2Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA
3Laboratoire de Pharmacie Galénique, Faculté de Pharmacie, 27 Bd Jean Moulin, Marseille 05 13385, France
Correspondence to: Dr J Ciccolini, EA3286, Laboratoire de Pharmacocinétique, Faculté de Pharmacie, 27 Bd Jean Moulin 13385, Marseille 05, France. E-mail: jo.ciccolini@pharmacie.univ-mrs.fr
Revised 18 July 2007; accepted 10 August 2007; published online 11 September 2007
Drug resistance is a major cause of treatment failure in cancer chemotherapy, including that with the extensively prescribed antimetabolite, 5-fluorouracil (5-FU). In this study, we tried to reverse 5-FU resistance by using a double-punch strategy: combining 5-FU with a biochemical modulator to improve its tumoural activation and encapsulating both these agents in one same stealth liposome. Experiments carried out in the highly resistant, canonical SW620 human colorectal model showed a up to 80% sensitisation to 5-FU when these cells were treated with our liposomal formulation. Results with this formulation demonstrated 30% higher tumoural drug uptake, better activation with increased active metabolites including critical-5-fluoro-2-deoxyuridine-5-monophosphate, superior inhibition (98%) of tumour thymidylate synthase, and subsequently, higher induction of both early and late apoptosis. Drug monitoring showed that higher and sustained exposure was achieved in rats treated with liposomal formulation. When examined in a xenograft animal model, our dual-agent liposomal formulation caused a 74% reduction in tumour size with a mean doubling in survival time, whereas standard 5-FU failed to exhibit significant antiproliferative activity as well as to increase the lifespan of tumour-bearing mice. Taken collectively, our data suggest that resistance to 5-FU can be overcome through a better control of its intratumoural activation and the use of an encapsulated formulation.
Keywords: stealth liposome; 5-FU; modulation; resistance; xenografts
back to top  |
| Article links | |
| ||
| ||
 | Send to a friend | |
 | Download PDF | |
| ||
| ||
| ||
 | Full text | |
| ||
| ||
| ||
 | Preceding article | |
 | Next article | |
 | Table of Contents | |
| ||
| ||
| ||
| ||
| ||
|
|
|
|
| |||
| Print ISSN: 0007-0920 | Online ISSN: 1532-1827 | © 2007 Cancer Research UK | ||
| |||
| Privacy Policy | |||